Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 90 of 95, showing 5 Applications out of 471 total, starting on record 446, ending on 450

# Protocol No Study Title Investigator(s) & Site(s)

446.

ECCT/23/04/02   Shigella 53G study in Kenya
    Safety and feasibility of a Shigella sonnei 53G controlled human infection model in Kenyan adults: a dose finding and dose verification study   
Principal Investigator(s)
1. Melissa Kapulu
2. Fredrick Sawe
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
View

447.

ECCT/19/08/01   Use of malaria infection by injection to study malaria transmission
    Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites   
Principal Investigator(s)
1. Melissa Kapulu
2. Philip Bejon
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
View

448.

ECCT/19/04/01   A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants.
    Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants   
Principal Investigator(s)
1. Mainga Hamaluba
2. Kosgei Josphat
Site(s) in Kenya
1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county)
2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county)
 
View

449.

ECCT/09/09/02   MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN
    SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN   
Principal Investigator(s)
1. LUCAS OTIENO TINA
2. MARY HAMEL
Site(s) in Kenya
1. KEMRI-CDC, (Siaya county)
2. KEMRI-WRP (Kisumu county)
 
View

450.

ECCT/20/06/01   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults   
Principal Investigator(s)
1. Prof Walter Jaoko Godfrey Jaoko
Site(s) in Kenya
1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county)
 
View